Literature DB >> 24909899

NREM sleep hypersomnia and reduced sleep/wake continuity in a neuroendocrine mouse model of anxiety/depression based on chronic corticosterone administration.

Y Le Dantec1, G Hache2, J P Guilloux2, B P Guiard2, D J David2, J Adrien3, P Escourrou4.   

Abstract

Sleep/wake disorders are frequently associated with anxiety and depression and to elevated levels of cortisol. Even though these alterations are increasingly sought in animal models, no study has investigated the specific effects of chronic corticosterone (CORT) administration on sleep. We characterized sleep/wake disorders in a neuroendocrine mouse model of anxiety/depression, based on chronic CORT administration in the drinking water (35 μg/ml for 4 weeks, "CORT model"). The CORT model was markedly affected during the dark phase by non-rapid eye movement sleep (NREM) increase without consistent alteration of rapid eye movement (REM) sleep. Total sleep duration (SD) and sleep efficiency (SE) increased concomitantly during both the 24h and the dark phase, due to the increase in the number of NREM sleep episodes without a change in their mean duration. Conversely, the total duration of wake decreased due to a decrease in the mean duration of wake episodes despite an increase in their number. These results reflect hypersomnia by intrusion of NREM sleep during the active period as well as a decrease in sleep/wake continuity. In addition, NREM sleep was lighter, with an increased electroencephalogram (EEG) theta activity. With regard to REM sleep, the number and the duration of episodes decreased, specifically during the first part of the light period. REM and NREM sleep changes correlated respectively with the anxiety and the anxiety/depressive-like phenotypes, supporting the notion that studying sleep could be of predictive value for altered emotional behavior. The chronic CORT model in mice that displays hallmark characteristics of anxiety and depression provides an insight into understanding the changes in overall sleep architecture that occur under pathological conditions.
Copyright © 2014 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  anxiety/depression; behavior; corticosterone; hypersomnia; sleep disorders; sleep/wake continuity

Mesh:

Substances:

Year:  2014        PMID: 24909899     DOI: 10.1016/j.neuroscience.2014.05.050

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  8 in total

Review 1.  Psychopharmacological properties and therapeutic profile of the antidepressant venlafaxine.

Authors:  Claire Rampon; Bruno P Guiard; Basile Coutens; Antoine Yrondi
Journal:  Psychopharmacology (Berl)       Date:  2022-08-10       Impact factor: 4.415

2.  Hypersomnia in Mood Disorders: a Rapidly Changing Landscape.

Authors:  David T Plante
Journal:  Curr Sleep Med Rep       Date:  2015-06

3.  Short-term sleep fragmentation enhances anxiety-related behavior: The role of hormonal alterations.

Authors:  Zeljko Grubac; Nikola Sutulovic; Anida Ademovic; Milica Velimirovic; Aleksandra Rasic-Markovic; Djuro Macut; Natasa Petronijevic; Olivera Stanojlovic; Dragan Hrncic
Journal:  PLoS One       Date:  2019-07-03       Impact factor: 3.240

4.  Learned Immobility Produces Enduring Impairment of the HPA Axis Reactivity in Mice without Replicating the Broad Spectrum of Depressive-Like Phenotype.

Authors:  Sébastien Bullich; Sarah Delcourte; Nasser Haddjeri; Bruno P Guiard
Journal:  Int J Mol Sci       Date:  2021-01-19       Impact factor: 5.923

Review 5.  Sleep Disturbances and Depression Are Co-morbid Conditions: Insights From Animal Models, Especially Non-human Primate Model.

Authors:  Meng Li; Jieqiong Cui; Bonan Xu; Yuanyuan Wei; Chenyang Fu; Xiaoman Lv; Lei Xiong; Dongdong Qin
Journal:  Front Psychiatry       Date:  2022-01-25       Impact factor: 4.157

6.  Attenuated Levels of Hippocampal Connexin 43 and its Phosphorylation Correlate with Antidepressant- and Anxiolytic-Like Activities in Mice.

Authors:  Gaël Quesseveur; Benjamin Portal; Jean-Arnaud Basile; Pascal Ezan; Alexia Mathou; Hélène Halley; Corinne Leloup; Xavier Fioramonti; Nicole Déglon; Christian Giaume; Claire Rampon; Bruno P Guiard
Journal:  Front Cell Neurosci       Date:  2015-12-22       Impact factor: 5.505

7.  Total Saikosaponins of Bupleurum yinchowense reduces depressive, anxiety-like behavior and increases synaptic proteins expression in chronic corticosterine-treated mice.

Authors:  Xiuping Sun; Xianglei Li; Ruile Pan; Yanfeng Xu; Qiong Wang; Mingjing Song
Journal:  BMC Complement Altern Med       Date:  2018-04-02       Impact factor: 3.659

8.  S 47445 Produces Antidepressant- and Anxiolytic-Like Effects through Neurogenesis Dependent and Independent Mechanisms.

Authors:  Indira Mendez-David; Jean-Philippe Guilloux; Mariusz Papp; Laurent Tritschler; Elisabeth Mocaer; Alain M Gardier; Sylvie Bretin; Denis J David
Journal:  Front Pharmacol       Date:  2017-07-19       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.